CA2544460A1 - Controlled-release biocompatible ocular drug delivery implant devices and methods - Google Patents

Controlled-release biocompatible ocular drug delivery implant devices and methods Download PDF

Info

Publication number
CA2544460A1
CA2544460A1 CA002544460A CA2544460A CA2544460A1 CA 2544460 A1 CA2544460 A1 CA 2544460A1 CA 002544460 A CA002544460 A CA 002544460A CA 2544460 A CA2544460 A CA 2544460A CA 2544460 A1 CA2544460 A1 CA 2544460A1
Authority
CA
Canada
Prior art keywords
methods
devices
controlled
release
drug delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002544460A
Other languages
French (fr)
Other versions
CA2544460C (en
Inventor
Vernon G. Wong
Mae W. L. Hu
Donald E. Berger, Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan, Inc.
Vernon G. Wong
Mae W. L. Hu
Donald E. Berger, Jr.
Oculex Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/426,141 external-priority patent/US6331313B1/en
Application filed by Allergan, Inc., Vernon G. Wong, Mae W. L. Hu, Donald E. Berger, Jr., Oculex Pharmaceuticals, Inc. filed Critical Allergan, Inc.
Publication of CA2544460A1 publication Critical patent/CA2544460A1/en
Application granted granted Critical
Publication of CA2544460C publication Critical patent/CA2544460C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Abstract

Controlled release devices are disclosed which are biocompatible and can be implanted into the eye. The devices have a core comprising a drug and a polymeric outer layer which is substantially impermeable to the entrance of an environmental fluid and substantially impermeable to the release of the drug during a delivery period, and drug release is affected through an orifice in the outer layer. These devices have an orifice area of less than 10 % of the total surface area of the device and can be used to deliver a variety of drugs with varying degrees of solubility and or molecular weight. Methods are also provided for using these drugs delivery devices.
CA002544460A 1999-10-22 2000-10-19 Controlled-release biocompatible ocular drug delivery implant devices and methods Expired - Lifetime CA2544460C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/426,141 US6331313B1 (en) 1999-10-22 1999-10-22 Controlled-release biocompatible ocular drug delivery implant devices and methods
US09/426,141 1999-10-22
CA002355313A CA2355313C (en) 1999-10-22 2000-10-19 Controlled-release biocompatible ocular drug delivery implant devices and methods

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA002355313A Division CA2355313C (en) 1999-10-22 2000-10-19 Controlled-release biocompatible ocular drug delivery implant devices and methods

Publications (2)

Publication Number Publication Date
CA2544460A1 true CA2544460A1 (en) 2001-05-03
CA2544460C CA2544460C (en) 2009-04-07

Family

ID=36702811

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002544460A Expired - Lifetime CA2544460C (en) 1999-10-22 2000-10-19 Controlled-release biocompatible ocular drug delivery implant devices and methods

Country Status (1)

Country Link
CA (1) CA2544460C (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011079232A1 (en) * 2009-12-23 2011-06-30 Psivida Us, Inc. Sustained release delivery devices
US8252307B2 (en) 1999-03-22 2012-08-28 Psivida Us, Inc. Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US8574613B2 (en) 2000-04-26 2013-11-05 Psivida Us, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US8871241B2 (en) 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8252307B2 (en) 1999-03-22 2012-08-28 Psivida Us, Inc. Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US8574613B2 (en) 2000-04-26 2013-11-05 Psivida Us, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US8574659B2 (en) 2000-04-26 2013-11-05 Psivida Us, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US9192579B2 (en) 2000-04-26 2015-11-24 Psivida Us, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US9849085B2 (en) 2000-04-26 2017-12-26 Psivida Us Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US8871241B2 (en) 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
WO2011079232A1 (en) * 2009-12-23 2011-06-30 Psivida Us, Inc. Sustained release delivery devices

Also Published As

Publication number Publication date
CA2544460C (en) 2009-04-07

Similar Documents

Publication Publication Date Title
CA2355313A1 (en) Controlled-release biocompatible ocular drug delivery implant devices and methods
US4898733A (en) Layered, compression molded device for the sustained release of a beneficial agent
WO2005013936A3 (en) Manufacture of long term drug delivery devices with polyurethane based polymers
CA2230947A1 (en) Implantable controlled release device to deliver drugs directly to an internal portion of the body
WO2001043749A3 (en) Pharmaceutical implant containing immediate-release and sustained-release components and method of administration
WO2002049535A3 (en) Medicated polymer-coated stent assembly
CA2395077A1 (en) Liquid composition of biodegradable block copolymer for drug delivery system and process for the preparation thereof
CA2531833A1 (en) Poly-4-hydroxybutyrate matrices for sustained drug delivery
CA2395333A1 (en) Hydrogel-driven drug dosage form
CA2367209A1 (en) Stent security balloon/balloon cathether
CA2375714A1 (en) Delayed total release two pulse gastrointestinal drug delivery system
CA2383499A1 (en) Drug delivery device
CA2305762A1 (en) Delayed total release gastrointestinal drug delivery system
WO2001008717A9 (en) Controlled release implantable devices
WO2002047731A3 (en) Drug delivery compositions and coated medical devices
WO2002011702A3 (en) Hydrogel-driven drug dosage form
ATE554806T1 (en) DEVICE FOR DELIVERING THERAPEUTIC AGENTS HAVING A SEPARATING PROTECTIVE LAYER
WO2005115493A3 (en) Thermal treatment of an implantable medical device
MY133883A (en) Gastrointestinal drug delivery system
WO2005025634A3 (en) Biointerface membranes incorporating bioactive agents
EP1125577A3 (en) Liquid drug delivery compositions
CA2513751A1 (en) Sustained release device and method for ocular delivery of adrenergic agents
AU2001291526A1 (en) Sustained release composition containing clarithromycin
WO2005065643A3 (en) Sutureless ophthalmic drug delivery system and method
CA2340898A1 (en) Compositions and methods for treating intracellular infections

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20201019